
==== Front
Target Oncol
Target Oncol
Targeted Oncology
1776-2596
1776-260X
Springer International Publishing Cham

39028410
1085
10.1007/s11523-024-01085-6
Correction
Correction to: Moving T‑Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review
http://orcid.org/0000-0002-9494-1877
Fowler Nathan Hale nathan.fowler@bostongene.com

1
http://orcid.org/0000-0002-2045-6238
Chavez Julio C. 2
http://orcid.org/0000-0003-2719-0580
Riedell Peter A. 3
1 grid.518683.1 BostonGene, Waltham, MA USA
2 https://ror.org/01xf75524 grid.468198.a 0000 0000 9891 5233 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL USA
3 https://ror.org/024mw5h28 grid.170205.1 0000 0004 1936 7822 David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL USA
19 7 2024
19 7 2024
2024
19 5 817817
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmc Correction to : Targeted Oncology (2024) 19:495–510 10.1007/s11523-024-01070-z

The article “Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review”, written by Nathan Hale Fowler, Julio C. Chavez and Peter A. Riedell, was originally published Online First without Open Access. After publication in volume 19, issue 4, page 495–510 the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2024 and the article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0

The original article has been corrected.
